Is Intellia Therapeutics Stock a Good Investment?
Intellia Therapeutics Investment Advice | NTLA |
- Examine Intellia Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Intellia Therapeutics' leadership team and their track record. Good management can help Intellia Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Intellia Therapeutics' business and its evolving consumer preferences.
- Compare Intellia Therapeutics' performance and market position to its competitors. Analyze how Intellia Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Intellia Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Intellia Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Intellia Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Intellia Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Intellia Therapeutics Stock
Researching Intellia Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 92.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Intellia Therapeutics recorded a loss per share of 5.25. The entity had not issued any dividends in recent years.
To determine if Intellia Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Intellia Therapeutics' research are outlined below:
| Intellia Therapeutics generated a negative expected return over the last 90 days | |
| Intellia Therapeutics has high historical volatility and very poor performance | |
| Intellia Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 57.88 M. Net Loss for the year was (481.19 M) with loss before overhead, payroll, taxes, and interest of (408.43 M). | |
| Intellia Therapeutics currently holds about 874.28 M in cash with (394.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: April 14, 2025 Deadline Contact Levi Korsinsky to Join Class Action Suit Against NTLA |
Intellia Therapeutics Quarterly Accounts Payable |
|
Intellia Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Intellia Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intellia Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Intellia Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Intellia Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-10-31 | 2017-09-30 | -0.5 | -0.44 | 0.06 | 12 | ||
2018-05-01 | 2018-03-31 | -0.58 | -0.51 | 0.07 | 12 | ||
2020-08-06 | 2020-06-30 | -0.69 | -0.61 | 0.08 | 11 | ||
2021-02-25 | 2020-12-31 | -0.6 | -0.69 | -0.09 | 15 | ||
2017-03-14 | 2016-12-31 | -0.22 | -0.31 | -0.09 | 40 | ||
2019-05-02 | 2019-03-31 | -0.59 | -0.49 | 0.1 | 16 | ||
2020-11-05 | 2020-09-30 | -0.59 | -0.47 | 0.12 | 20 | ||
2021-11-04 | 2021-09-30 | -0.84 | -0.97 | -0.13 | 15 |
Intellia Therapeutics Target Price Consensus
Intellia target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Intellia Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 28 | Strong Buy |
Most Intellia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Intellia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Intellia Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIntellia Therapeutics Target Price Projection
Intellia Therapeutics' current and average target prices are 8.68 and 57.76, respectively. The current price of Intellia Therapeutics is the price at which Intellia Therapeutics is currently trading. On the other hand, Intellia Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Intellia Therapeutics Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Intellia Therapeutics Target Price
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Intellia Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Intellia Therapeutics' financials, market performance, and future outlook by experienced professionals. Intellia Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Intellia Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Intellia Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intellia Therapeutics backward and forwards among themselves. Intellia Therapeutics' institutional investor refers to the entity that pools money to purchase Intellia Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Contrarius Investment Management Ltd | 2024-09-30 | 2 M | Goldman Sachs Group Inc | 2024-12-31 | 2 M | Casdin Capital, Llc | 2024-12-31 | 2 M | Two Sigma Advisers, Llc | 2024-12-31 | 2 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 2 M | Two Sigma Investments Llc | 2024-12-31 | 1.8 M | Ubs Group Ag | 2024-12-31 | 1.7 M | Voloridge Investment Management, Llc | 2024-12-31 | 1.5 M | Fmr Inc | 2024-12-31 | 1.3 M | Ark Investment Management Llc | 2024-12-31 | 12.5 M | Blackrock Inc | 2024-12-31 | 10.9 M |
Intellia Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 963.74 M.Market Cap |
|
Intellia Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.60) | (0.62) |
Determining Intellia Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Intellia Therapeutics is a good buy. For example, gross profit margin measures Intellia Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Intellia Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Intellia Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.
Evaluate Intellia Therapeutics' management efficiency
Intellia Therapeutics has return on total asset (ROA) of (0.268) % which means that it has lost $0.268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5401) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 25, 2025, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.52. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 578.7 M, whereas Total Assets are forecasted to decline to about 743.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.82 | 8.01 | |
| Tangible Book Value Per Share | 8.82 | 8.01 | |
| Enterprise Value Over EBITDA | (2.24) | (2.35) | |
| Price Book Value Ratio | 1.32 | 2.58 | |
| Enterprise Value Multiple | (2.24) | (2.35) | |
| Price Fair Value | 1.32 | 2.58 | |
| Enterprise Value | 803.7 K | 714.4 K |
The decision-making processes within Intellia Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.969 |
Basic technical analysis of Intellia Stock
As of the 25th of March, Intellia Therapeutics retains the Market Risk Adjusted Performance of (0.26), standard deviation of 4.82, and Risk Adjusted Performance of (0.07). Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of Intellia Therapeutics, as well as the relationship between them.Intellia Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intellia Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intellia Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intellia Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Intellia Therapeutics' Outstanding Corporate Bonds
Intellia Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Intellia Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Intellia bonds can be classified according to their maturity, which is the date when Intellia Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US45824TBC80 Corp BondUS45824TBC80 | View | |
| IFCCN 5459 22 SEP 32 Corp BondUS45823TAL08 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| INTELLIGENT PACKAGING LTD Corp BondUS45827MAA53 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Intellia Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Intellia Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.71 | |||
| Coefficient Of Variation | (1,115) | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.24 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 20.66 | |||
| Value At Risk | (7.56) | |||
| Potential Upside | 7.76 | |||
| Skewness | (0.03) | |||
| Kurtosis | 0.6732 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.71 | |||
| Coefficient Of Variation | (1,115) | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.24 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 20.66 | |||
| Value At Risk | (7.56) | |||
| Potential Upside | 7.76 | |||
| Skewness | (0.03) | |||
| Kurtosis | 0.6732 |
Consider Intellia Therapeutics' intraday indicators
Intellia Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intellia Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 8.68 | |||
| Day Typical Price | 8.68 | |||
| Price Action Indicator | (0.32) | |||
| Period Momentum Indicator | (0.63) | |||
| Relative Strength Index | 43.63 |
Intellia Therapeutics Corporate Filings
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 28th of February 2025 Other Reports | ViewVerify | |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 23rd of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Intellia Stock media impact
Far too much social signal, news, headlines, and media speculation about Intellia Therapeutics that are available to investors today. That information is available publicly through Intellia media outlets and privately through word of mouth or via Intellia internal channels. However, regardless of the origin, that massive amount of Intellia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Intellia Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intellia Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intellia Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intellia Therapeutics alpha.
Intellia Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Intellia Therapeutics Historical Investor Sentiment
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.
Intellia Therapeutics Corporate Management
| JD Esq | General VP | Profile | |
| Jennifer Doudna | Founder Board | Profile | |
| Derek Hicks | Executive Officer | Profile | |
| Andrew May | Founder Board | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.25) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Intellia Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.